Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which oxidative stress drives amyloid beta accumulation and neuronal damage. Fluid‐based oxidative stress–related biomarkers offer promising, minimally invasive platforms for early detection, with this review evaluating their diagnostic potential. Following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, a systematic search of PubMed, Scopus, and Google Scholar identified human studies published between 2000 and 2025 examining fluid‐based oxidative stress–related biomarkers in individuals with AD. Elevated lipid peroxidation markers (malondialdehyde, 4‐hydroxynonenal, and 1‐palmitoyl‐2‐5′‐oxovaleroyl‐sn‐glycero‐3‐phosphocholine) were consistently linked to AD and cognitive decline. Antioxidant enzymes (superoxide dismutase, glutathione GSH peroxidase, and catalase) showed reductions, while GSH and the GSH:oxidized GSH ratio emerged as robust indicators of redox imbalance in AD. Urinary 8‐hydroxyguanosine demonstrated compartment‐specific sensitivity. Altered trace elements (low selenium, iron, uric acid, and high copper) reflected systemic disruption in AD. Peripheral oxidative stress–related biomarkers offer scalable, minimally invasive avenues for AD diagnosis and monitoring, supporting improved clinical decision making.
Osei et al. (Wed,) studied this question.